The MCO-Ci 400 represents a novel approach in hemodialysis treatment, potentially addressing chronic inflammation in patients with end-stage renal disease (ESRD). Given the increasing prevalence of chronic kidney disease (CKD) and the limitations of current dialysis technologies, this innovation could capture significant market share. The collaboration with established entities such as Baxter Healthcare and Gambro Dialysatoren enhances credibility and market access. The completion of this trial positions Vantive Health LLC favorably for potential partnerships or acquisitions, especially if the results demonstrate significant clinical benefits over existing high-flux dialysis membranes.